Abstract:Background: Recent evidence has indicated that alterations in energy metabolism play a critical role in the pathogenesis of fibrotic diseases. Studies have suggested that 'metabolic reprogramming' involving the glycolysis and oxidative phosphorylation (OXPHOS) in cells lead to an enhanced generation of energy and biosynthesis. The aim of this study was to assess the molecular basis of changes in fibrotic metabolism in systemic sclerosis (Scleroderma; SSc) and highlight the most appropriate targets for anti-fibrotic therapies. Materials and methods: Dermal fibroblasts were isolated from five SSc patients and five healthy donors. Cells were cultured in medium with/without TGF-β1 and with/without ALK5, pan-PIM or ATM kinase inhibitors. Extracellular flux analyses were performed to evaluate glycolytic and mitochondrial respiratory function. The mitochondrial network in TMRM-stained cells was visualized by confocal laser-scanning microscopy, followed by semi-automatic analysis on the ImageJ platform. Protein expression of ECM and fibroblast components, glycolytic enzymes, subunits of the five OXPHOS complexes, and dynamin-related GTPases and receptors involved in mitochondrial fission/fusion were assessed by western blotting. Results: Enhanced mitochondrial respiration coupled to ATP production was observed in SSc fibroblasts at the expense of spare respiratory capacity. Although no difference was found in glycolysis when comparing SSc with healthy control fibroblasts, levels of phophofructokinase-1 isoform PFKM were significantly lower in SSc fibroblasts ( P <0.05). Our results suggest that the number of respirasomes is decreased in the SSc mitochondria; however, the organelles formed a hyperfused network, which is thought to increase mitochondrial ATP production through complementation. The increased mitochondrial fusion correlated with a change in expression levels of regulators of mitochondrial morphology, including decreased levels of DRP1, increased levels of MIEF2 and changes in OPA1 isoform ratios. TGF-β1 treatment strongly stimulated glycolysis and mitochondrial respiration and induced the expression of fibrotic markers. The pan-PIM kinase inhibitor had no effect, whereas both ALK5 and ATM kinase inhibition abrogated TGF-β1-mediated fibroblast activation, and upregulation of glycolysis and respiration. Conclusions: Our data provide evidence for a novel mechanism(s) by which SSc fibroblasts exhibit altered metabolic programs and highlight changes in respiration and dysregulated mitochondrial morphology and function, which can be selectively targeted by small molecule kinase inhibitors.

Molecular Profiling Reveals a Common Metabolic Signature of Tissue Fibrosis

Acetate Controls Endothelial-to-mesenchymal Transition

Exploring metabolism in scleroderma reveals opportunities for pharmacological intervention for therapy in fibrosis

TGF2 and TGF3 isoforms drive fibrotic disease pathogenesis

P003 Metabolic Reprogramming in Intestinal Fibrosis: Integrating Metabolomics, Single-Cell Transcriptomics and Isotope Tracing

Metabolic Characterization and RNA Profiling Reveal Glycolytic Dependence of Profibrotic Phenotype of Alveolar Macrophages in Lung Fibrosis

ATF4 and mTOR regulate metabolic reprogramming in TGF-β-treated lung fibroblasts

Dynamic multi-omics and mechanistic modeling approach uncovers novel mechanisms of kidney fibrosis progression

Spatial metabolomics reveals glycogen as an actionable target for pulmonary fibrosis

A New Hypothetical Concept in Metabolic Understanding of Cardiac Fibrosis: Glycolysis Combined with TGF-β and KLF5 Signaling

Integrative Proteo-Transcriptomic Characterization of Advanced Fibrosis in Chronic Liver Disease Across Etiologies

Pyruvate metabolism dictates fibroblast sensitivity to GLS1 inhibition during fibrogenesis

Metabolic reprogramming of pulmonary fibrosis

Glycolytic Reprogramming in Myofibroblast Differentiation and Lung Fibrosis.

Characterization of Pro-Fibrotic Signaling Pathways using Human Hepatic Organoids

Targeting fatty acid metabolism for fibrotic disorders

Matrisome Gene-Based Subclassification of Patients with Liver Fibrosis Identifies Clinical and Molecular Heterogeneities.

Impaired AMPK Control of Alveolar Epithelial Cell Metabolism Promotes Pulmonary Fibrosis

Macrophage-derived cathepsin S remodels the extracellular matrix to promote liver fibrogenesis

Pharmacological targeting of AMPK to restore glucose and fatty acid metabolism homeostasis attenuates transplanted kidney fibrosis